Prime Medicine (NASDAQ:PRME) Stock Price Down 5.6% - What's Next?

Key Points

• Prime Medicine's stock fell by 5.6% on Friday, trading as low as $4.87, with a significant decline in trading volume—59% lower than the average.
• Wall Street Zen downgraded the company's rating from "hold" to a "sell" rating as of September 2nd.
• Prime Medicine has a market capitalization of $678.23 million and a negative PE ratio of -3.23, indicating financial challenges facing the company.

Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report) fell 5.6% on Friday . The stock traded as low as $4.87 and last traded at $4.93. 1,086,398 shares changed hands during trading, a decline of 59% from the average session volume of 2,620,316 shares. The stock had previously closed at $5.22.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered Prime Medicine from a "hold" rating to a "sell" rating in a research note on Tuesday, September 2nd.

Prime Medicine Stock Down 3.4%

The company has a market cap of $678.23 million, a PE ratio of -3.23 and a beta of 2.38.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.